Different in vivo functions of the two catalytic domains of angiotensin-converting enzyme (ACE)
- 2 December 2010
- journal article
- review article
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 11 (2), 105-111
- https://doi.org/10.1016/j.coph.2010.11.001
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Angiotensin-Converting Enzyme N-Terminal Inactivation Alleviates Bleomycin-Induced Lung InjuryThe American Journal of Pathology, 2010
- Crystal structure of a phosphonotripeptide K-26 in complex with angiotensin converting enzyme homologue (AnCE) from Drosophila melanogasterBiochemical and Biophysical Research Communications, 2010
- N -Acetyl-Seryl-Aspartyl-Lysyl-Proline Attenuates Renal Injury and Dysfunction in Hypertensive Rats With Reduced Renal MassHypertension, 2010
- Misdiagnosis and mistreatment of a common side‐effect – angiotensin‐converting enzyme inhibitor‐induced coughBritish Journal of Clinical Pharmacology, 2010
- Aβ42-to-Aβ40- and Angiotensin-converting Activities in Different Domains of Angiotensin-converting EnzymeJournal of Biological Chemistry, 2009
- Prevention of aortic fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in angiotensin II-induced hypertensionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?The International Journal of Biochemistry & Cell Biology, 2007
- Ac-SDKP Reverses Cardiac Fibrosis in Rats With Renovascular HypertensionHypertension, 2003
- S 17092-1, a Highly Potent, Specific and Cell Permeant Inhibitor of Human Proline EndopeptidaseBiochemical and Biophysical Research Communications, 1999
- N-Domain–Specific Substrate and C-Domain Inhibitors of Angiotensin-Converting EnzymeHypertension, 1998